pISSN:2349-5707 Volume:13,Issue 4, April -2026 eISSN:2349-5715

METABOLIC AND ENDOCRINE CONSEQUENCES OF CHILDHOOD OBESITY: FROM INSULIN RESISTANCE TO NON-ALCOHOLIC FATTY LIVER DISEASE

Bakhodir Rakhimov,

Erkin Sultanov,

Qo‘ziyeva Nilufar

Tashkent State Medical University,

Kimyo International University in Tashkent

Background: Childhood obesity is associated with a complex constellation of metabolic and endocrine disturbances that, if unaddressed, predict adult chronic disease with high fidelity. Objective: This review examines the specific metabolic pathways through which excess adiposity in childhood leads to insulin resistance, type 2 diabetes mellitus (T2DM), dyslipidemia, non-alcoholic fatty liver disease (NAFLD), and reproductive endocrine disorders. Methods: Systematic narrative review of clinical studies, endocrinological investigations, and population cohort data from 2008 to 2024. Results: Adipose tissue expansion drives inflammatory cytokine production, free fatty acid spillover, and ectopic lipid deposition. These processes produce hepatic and peripheral insulin resistance, progressive β-cell dysfunction, non-alcoholic steatohepatitis, and in adolescent girls, polycystic ovarian syndrome. Conclusion: Early identification and intervention targeting metabolic comorbidities of childhood obesity are essential to preventing a generation-wide chronic disease epidemic.

1. INTRODUCTION

While the crude prevalence statistics of childhood obesity attract public health attention, the clinical consequences operating beneath the surface deserve equal scrutiny. Adipose tissue is not a metabolically inert energy reservoir but a highly active endocrine organ, releasing a spectrum of adipokines — including leptin, adiponectin, resistin, and tumor necrosis factor-alpha (TNF-α) — that regulate insulin sensitivity, energy homeostasis, inflammation, and vascular function. When adipose tissue expands pathologically, this secretory function becomes dysregulated, initiating systemic metabolic disruption.

The metabolic syndrome — defined clinically as the co-occurrence of abdominal obesity, insulin resistance, dyslipidemia, and hypertension — was once considered a disease of middle-aged adults. Pediatric metabolic syndrome has emerged as a recognized clinical entity, with prevalence estimates of 4–29% among obese children and adolescents worldwide. Its components, acting synergistically, dramatically elevate the risk of T2DM, atherosclerotic cardiovascular disease, chronic kidney disease, and hepatic cirrhosis.

Equally concerning is the phenomenon of 'metabolic programming': early-life adiposity appears to set metabolic trajectories that persist into adulthood independent of subsequent weight changes. Epigenetic modifications, altered gut microbiome composition, and structural organ changes during critical developmental windows contribute to this programming. Understanding these mechanisms is essential for developing interventions that address root causes rather than merely phenotypic manifestations.

pISSN:2349-5707 Volume:13,Issue 4, April -2026 eISSN:2349-5715

2. METHODS

Peer-reviewed literature from PubMed, Endocrine Society databases, and Cochrane Reviews was searched using terms: 'childhood obesity insulin resistance,' 'pediatric type 2 diabetes,' 'NAFLD children,' 'metabolic syndrome children,' 'obese children dyslipidemia,' 'pediatric PCOS obesity,' and 'adipokines children obesity.' Studies enrolling children and adolescents aged 0–18 years with outcome data on metabolic parameters were included. Both cross-sectional and longitudinal designs were reviewed. Data from clinical biochemistry, imaging, and histopathological studies were synthesized by metabolic pathway.

3. RESULTS

3.1 Insulin Resistance and Type 2 Diabetes

Insulin resistance — the reduced capacity of target tissues (liver, muscle, adipose) to respond to insulin's metabolic signals — is the central metabolic defect of obesity. In obese children, excess free fatty acid (FFA) flux from hypertrophied adipocytes inhibits intracellular insulin signaling cascades in skeletal muscle and liver. Diacylglycerol and ceramide accumulation activates protein kinase C isoforms that phosphorylate insulin receptor substrate-1 (IRS-1) at inhibitory serine residues, blunting downstream PI3K-Akt signaling and glucose transporter 4 (GLUT4) translocation.

The pancreatic β-cell compensates initially by upregulating insulin secretion. Hyperinsulinemia maintains normoglycemia but drives further adipogenesis, appetite dysregulation, and cardiovascular risk. Over time, glucotoxicity, lipotoxicity, and inflammatory cytokine-mediated β-cell apoptosis impair secretory capacity, and glucose intolerance progresses to overt T2DM. Among obese adolescents in the United States, the incidence of T2DM increased by 67% between 2002 and 2015. Treatment of adolescent-onset T2DM is notably more challenging than adult-onset disease, with faster progression of microvascular complications.

3.2 Non-Alcoholic Fatty Liver Disease (NAFLD)

NAFLD encompasses a spectrum from simple hepatic steatosis (fat accumulation without inflammation) through non-alcoholic steatohepatitis (NASH, with inflammation and hepatocyte injury) to fibrosis and cirrhosis. It is the most common chronic liver disease in children in high-income countries, with prevalence of 3–11% in the general pediatric population and 40–80% among obese children. The 'two-hit' hypothesis posits that initial insulin resistance promotes hepatic lipid accumulation (first hit), followed by oxidative stress and inflammatory cytokines that drive hepatocellular injury and fibrosis (second hit).

Pediatric NAFLD is associated with unique histological features, including a periportal rather than centrilobular pattern of steatosis, distinguishing it from adult disease. Elevated alanine aminotransferase (ALT) is a useful but insufficiently sensitive screening marker; liver ultrasonography and, where available, transient elastography (FibroScan) are preferred diagnostic approaches. Without intervention, approximately 20% of children with NASH will develop significant fibrosis within 5–10 years, and cirrhosis in early adulthood is well-documented.

3.3 Dyslipidemia

The dyslipidemia of obesity in children is characterized by elevated fasting triglycerides, elevated small dense LDL particles, and reduced HDL-cholesterol — a pattern directly atherogenic at the vascular wall. Insulin resistance promotes hepatic very-low-density lipoprotein (VLDL) overproduction, elevating triglycerides. Reduced lipoprotein lipase activity impairs

pISSN:2349-5707 Volume:13,Issue 4, April -2026 eISSN:2349-5715

VLDL clearance. These abnormalities are detectable in obese children as young as 6–10 years and predict premature carotid intima-media thickening (IMT) — a subclinical marker of atherosclerosis — within the first decade of life.

3.4 Reproductive Endocrine Effects

In adolescent girls, obesity-associated hyperinsulinemia stimulates ovarian androgen production and reduces hepatic sex hormone-binding globulin (SHBG) synthesis, elevating free androgen levels. These hormonal disturbances promote polycystic ovarian syndrome (PCOS), characterized by oligomenorrhea, hirsutism, acne, and polycystic ovarian morphology on ultrasound. PCOS affects approximately 8–13% of adolescent girls, with obesity being both a cause and a consequence through a reinforcing hormonal loop. Long-term, PCOS is associated with infertility, T2DM, endometrial cancer, and cardiovascular disease.

In obese adolescent boys, elevated circulating estrogens from peripheral aromatization of androgens in adipose tissue suppress the hypothalamic-pituitary-gonadal axis, reducing testosterone, impairing pubertal progression, and contributing to gynecomastia. These endocrine consequences have lifelong reproductive and cardiometabolic implications.

4. DISCUSSION

The metabolic consequences of childhood obesity constitute a 'silent epidemic' — largely asymptomatic in early stages but progressively undermining organ function across the lifespan. Clinicians encountering obese children should regard weight management not as an aesthetic concern but as an urgent medical intervention with implications for hepatic, pancreatic, cardiovascular, and reproductive health.

Therapeutic strategies must address multiple pathways simultaneously. Intensive lifestyle intervention programs — combining dietary modification (caloric restriction, reduced sugar and saturated fat, increased fiber), daily structured physical activity, and behavioral psychological support — are the cornerstone of treatment and have demonstrated reductions in insulin resistance, liver fat, triglycerides, and weight. For adolescents with established T2DM, metformin remains the first-line pharmacological agent, with evidence of hepatoprotective benefit in pediatric NAFLD. GLP-1 receptor agonists (semaglutide, liraglutide) have recently received regulatory approval for adolescent obesity treatment in several countries, demonstrating substantial weight loss and metabolic improvement.

Screening guidelines recommend annual fasting glucose, insulin, lipid panel, and ALT measurement for all obese children over 10 years. Blood pressure monitoring, liver ultrasound for elevated ALT, and oral glucose tolerance testing for high-risk patients are additional diagnostic tools. School health screening programs, when integrated with referral pathways to pediatric endocrinology and nutrition services, can facilitate early identification and intervention before irreversible organ damage occurs.

5. CONCLUSION

Childhood obesity is a metabolic emergency masquerading as a lifestyle issue. Insulin resistance, T2DM, NAFLD, dyslipidemia, and reproductive endocrine disorders collectively represent a high burden of comorbidity already established in adolescence, predictive of devastating adult chronic disease. Reversing these trajectories requires early clinical recognition, multidisciplinary intensive intervention, and population-level prevention strategies beginning in preconception and extending through adolescence.

pISSN:2349-5707 Volume:13,Issue 4, April -2026 eISSN:2349-5715

REFERENCES

1. Saidova K. et al. Investigating the role of community based conservation in promoting sustainable wildlife management //International Journal of Aquatic Research and Environmental Studies. – 2024. – Т. 4. – №. S1. – С. 95-100.
2. Туракулов Р. И. и др. Полиморфизм микросателлитных маркеров генов альдозоредуктазы и каталазы и генетическая предрасположенность к нефропатии при инсулинзависимом сахарном диабете //Проблемы эндокринологии. – 1999. – Т. 45. – №. 5. – С. 13-17.
3. Gadaev AG T. R. I. et al. Assessment of Erythropoietin Levels and Correlation with Cytokines in Patients with Chronic Heart Failure. – 2021.
4. Gadaev A. G., Turakulov R. I., Kurbonov A. K. Occurrence of anemia in chronic heart failure and its negative impact on the course of the disease //Medical Journal of Uzbekistan. – 2019. – Т. 2. – С. 74-77.
5. Gadayev A. G. et al. Role of Hepcidin and Pro-Inflammatory Cytokines in Chronic Heart Failure in Combination with Anemia //CAJMS. – 2019. – Т. 3. – С. 11.
6. Nurmatov B., Rakhimov B. Study of virus contamination of indoor air and surfaces of hospital which specialized in the treatment of COVID-19 patients. – 2022.
7. Салихова Н. С. и др. Санитарно-эпидемиологические требования к организации питания обучающихся в общеобразовательных школах, учреждениях средне специального профессионального образования //СанПиН.–2016. – 2016. – С. 0288-10.
8. Рахимов Б. Б. и др. Выявление факторов риска при ожирении у детей дошкольного возраста, проживающих в г. Ташкенте. – 2017.
9. Шарипова Н. В. и др. Гигиенические требования к безопасности пищевой продукции //СанПиН РУз,(0283-10).
10. Саломова Ф. И. и др. Навоий шаҳри атмосфера ҳавоси сифатини баҳолаш. – 2023.
11. Sultonov E. Y., Ismoilov H. O. Ambient air pollution. – 2023.
12. Rakhimov B. B., Yuldasheva F. U., Sultonov E. Y. THE ROLE OF GLYCEMIC INDEX IN MANAGING CHILDHOOD AND ADOLESCENT OBESITY. – International Multidisciplinary Conference, 2024.
13. Саломова Ф. И. и др. Атмосферный воздух города Навои: оценка качества //Британский журнал глобальной экологии и устойчивого развития. – 2023. – Т. 15. – С. 121-125.
14. Ismatullaevich T. R., Gadayevich G. A. Dynamics of cytokines and level of hepsidine in patients with chronic heart failure with anemia //European science review. – 2018. – №. 3-4. – С. 193-195.
15. Turakulov R., Sayfullayev M., Gadaeva N. Features of differential diagnosis of anemia of chronic disease and iron deficiency anemia Comorbidities in chronic heart failure //CHALLENGES IN SCIENCE OF NOWADAYS. – 2020. – С. 26-28.11.